More Updates from ASH 2010

An increased TIL count in the breast tissue was associated with improved distant recurrence-free survival in patients with triple-negative breast cancer.

Experts discuss findings related to gastrointestinal cancer outcomes as well as treatment inequalities presented at the 2024 SSO Annual Meeting.

The phase 3 TOPAZ-1 trial of durvalumab plus chemotherapy showed a significant benefit vs chemotherapy alone for patients with advanced biliary tract cancer.

Leaders in genitourinary oncology spoke about key research advances as well as personal experiences in navigating the field.

Several presentations from the 41st Annual Miami Breast Cancer Conference focused on new and evolving data in the space, according to Neil M. Iyengar, MD.

Additional data and results from the phase 3 STARGLO trial of glofitamab for patients with relapsed/refractory diffuse large B-cell lymphoma will be presented at an upcoming medical meeting.